Octafama focuses on the challenges of hemophilia A inhibitor management

Lagen, Switzerland, January 20, 2022 / PRNewswire/ -- A virtual workshop on Wednesday, February 2, 2022 at 6 p.m. CET will tell the touching story of the Rodriguez family and their two sons with hemophilia A in addressing the challenges of inhibitor management.

Inhibitor formation in coagulation factor VIII (FVIII) replacement therapy remains a major concern for patients with hemophilia type A and their families These issues may be particularly important for families who have previously developed inhibitors in vivo, as they have experienced many challenges of coexisting with inhibitors, including an increased risk of bleeding and increased dependence on ineffective bleeding management therapies, so there is a strong desire to minimize the risk of inhibitor formation, It is also hoped that effective methods will be taken to eliminate inhibitors that appear in patients.

Titled "A Family Story: Addressing Key Inhibitor Management Challenges for Hemophilia A," the satellite virtual workshop highlights the challenges facing Jacqueline, Justin, and their two sons, Justin, and their two sons, Justin, and Jace, which will be moderated by Dr. William Beau Mitchell of Montefiore Children's Hospital in Bronx, New York, saying, "For parents, It is very important for their children to receive excellent all-round bleeding prevention, so not producing inhibitors is an important factor in the implementation of effective treatment"

During the symposium, renowned world-class clinicians will discuss the story of the Rodriguez family and the family's experience with human cell line-derived recombinant FVIII products, and important clinical issues will be presented and discussed, including the need for bleeding prevention and inhibitor minimization in previously untreated children, the use of immune tolerance induction (ITI) elimination inhibitors, and future clinical studies in inhibitor management.

Laraisa Belyanskaya, Director of Hematology at Octapharma IBU, commented: "By talking to patients and their families, we know that the issue of FVIII inhibitor formation remains an important concern At Octapharma, we are committed to providing solutions aimed at minimizing the formation of inhibitors in patients with type A hemophilia"

Olaf Walter, a member of the Octapharma Board of Directors, added: "At Octapharma, we are committed to improving the lives of our patients, and the first-hand experience of people with hemophilia A and their families is a further reminder of the importance of our work."

To learn more about Octapharma's activities at the European Society for Hemophilia and Related Diseases 2022 (EAHAD) Virtual Congress, please visit the link here.